Literature DB >> 12531851

Anticoagulation in hospitals and general practice.

Andrew D Blann1, David A Fitzmaurice, Gregory Y H Lip.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12531851      PMCID: PMC1128888          DOI: 10.1136/bmj.326.7381.153

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  7 in total

Review 1.  Why maximum tolerated dose?

Authors:  Hans G Stampfer; Genevieve M Gabb; Simon B Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

Review 2.  Antithrombotic dose: Some observations from published clinical trials.

Authors:  Simon B Dimmitt; Christopher N Floyd; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-07-01       Impact factor: 4.335

3.  Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Authors:  Walid Amara; Sotiris Antoniou
Journal:  Eur Heart J Suppl       Date:  2016-04-21       Impact factor: 1.803

4.  Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.

Authors:  Kyung Hee Choi; Ah Jeong Kim; In Ja Son; Kyung-Hwan Kim; Ki-Bong Kim; Hyuk Ahn; Eun Bong Lee
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

5.  Breaks in continuity of care and the rural senior transferred for medical care under regionalisation.

Authors:  H Jay Biem; H Hadjistavropoulos; Debra Morgan; Henry B Biem; Raymond W Pong
Journal:  Int J Integr Care       Date:  2003-09-29       Impact factor: 5.120

6.  Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more.

Authors:  Maia Gavronski; Sirpa Hartikainen; Alexander Zharkovsky
Journal:  Pharm Pract (Granada)       Date:  2012-03-31

7.  Modeling patients' time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants.

Authors:  Aapeli Leminen; Mikko Pyykönen; Juho Tynkkynen; Markku Tykkyläinen; Tiina Laatikainen
Journal:  BMC Health Serv Res       Date:  2019-11-27       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.